Kadioglu A, Tefekli A, Köksal T, Usta M, Erol H
Department of Urology, Medical Faculty of Istanbul, University of Istanbul, Turkey.
Int J Impot Res. 2000 Jun;12(3):169-75. doi: 10.1038/sj.ijir.3900519.
As recent clinical and animal studies have indicated, colchicine, with its anti-fibrotic, anti-mitotic and anti-inflammatory activities, has suppressive effects in the pathogenesis of Peyronie's disease. Oral colchicine treatment was initiated in 60 Peyronie's patients during their acute phase (mean duration of disease: 5.7 +/- 4.3 months). Long-term results, based on changes of subjective and objective criteria, were assessed and predictive factors of successful outcome were investigated. After a mean follow-up of 10.7 +/- 4.7 months, the penile deformity improved in 30%, remained unchanged in 48.3% and deteriorated in 21.7%. Pain resolved in 95%. Best results were obtained in those with no risk factor for vascular disease, presenting during the initial 6 months of disease, degree of curvature <30 degrees, no erectile dysfunction by history and positive response to combined injection and stimulation test. In conclusion since tunica albuginea is affected as a whole in Peyronie's disease, systemic oral agents, such as colchicine, may be preferred in the early phase of the disease.
正如最近的临床和动物研究表明，秋水仙碱具有抗纤维化、抗有丝分裂和抗炎活性，在佩罗尼氏病的发病机制中具有抑制作用。对60例处于急性期的佩罗尼氏病患者（疾病平均病程：5.7±4.3个月）开始口服秋水仙碱治疗。基于主观和客观标准的变化评估长期结果，并研究成功结果的预测因素。平均随访10.7±4.7个月后，阴茎畸形改善的占30%，不变的占48.3%，恶化的占21.7%。95%的患者疼痛消失。在无血管疾病危险因素、疾病最初6个月内发病、弯曲度<30度、既往无勃起功能障碍且联合注射和刺激试验呈阳性反应的患者中取得了最佳结果。总之，由于佩罗尼氏病中白膜整体受累，在疾病早期可能首选秋水仙碱等全身性口服药物。
